These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 17319021)

  • 21. Bisphosphonate therapy and dental treatment.
    Phillips G
    J Indiana Dent Assoc; 2007-2008 Winter; 86(4):4-8. PubMed ID: 18363257
    [No Abstract]   [Full Text] [Related]  

  • 22. A once-yearly IV bisphosphonate for osteoporosis.
    Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523
    [No Abstract]   [Full Text] [Related]  

  • 23. [Treatment and prevention of osteoporosis in patients with decreased renal function].
    Vestergaard P; Eiken PA
    Ugeskr Laeger; 2008 Jan; 170(4):227-30. PubMed ID: 18282452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Annual zoledronic acid for osteoporosis.
    BMJ Group
    Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interventions to improve inpatient osteoporosis management following first osteoporotic fracture: the PREVENT project.
    Carpintero P; Gil-Garay E; Hernández-Vaquero D; Ferrer H; Munuera L
    Arch Orthop Trauma Surg; 2009 Feb; 129(2):245-50. PubMed ID: 19125257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonates: a once-yearly treatment option with Reclast.
    Van Gilder D
    S D Med; 2008 Nov; 61(11):416-7. PubMed ID: 19066136
    [No Abstract]   [Full Text] [Related]  

  • 27. Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models.
    Zambon A; Baio G; Mazzaglia G; Merlino L; Corrao G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):260-9. PubMed ID: 18240162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteoporosis treatment and fracture outcomes.
    Lindsay R
    JAMA Intern Med; 2015 Jun; 175(6):921-2. PubMed ID: 25866943
    [No Abstract]   [Full Text] [Related]  

  • 29. The search for good compliance: economic aspects of a conveyed combination pharmaco-therapy, exemplified by an osteoporosis therapy.
    Oberender P; Zerth J
    Eur J Health Econ; 2008 May; 9(2):127-36. PubMed ID: 17447094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral bisphosphonates and osteonecrosis of the jaw.
    Wynn RL
    Gen Dent; 2007; 55(1):8-10. PubMed ID: 17333956
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
    Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y
    Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients.
    Chae YS; Kim JG; Moon JH; Kim SN; Lee SJ; Kim YJ; Sohn SK
    Bone Marrow Transplant; 2009 Jul; 44(1):35-41. PubMed ID: 19139732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weekly osteoporosis treatments also problematic.
    Health News; 2005 Apr; 11(4):15. PubMed ID: 15816094
    [No Abstract]   [Full Text] [Related]  

  • 34. [Counseling of osteoporosis patients. To take time for the patient].
    Semler J
    MMW Fortschr Med; 2005 Aug; 147(31-32):45. PubMed ID: 16128199
    [No Abstract]   [Full Text] [Related]  

  • 35. Dosing Strategies of Bone-Targeting Agents.
    Uzoigwe CE
    JAMA Intern Med; 2015 Nov; 175(11):1865. PubMed ID: 26524745
    [No Abstract]   [Full Text] [Related]  

  • 36. Dosing Strategies of Bone-Targeting Agents.
    Hutton B; Mazzarello S; Clemons M
    JAMA Intern Med; 2015 Nov; 175(11):1864-5. PubMed ID: 26524744
    [No Abstract]   [Full Text] [Related]  

  • 37. Dosing Strategies of Bone-Targeting Agents-Reply.
    Greenspan SL; Perera S; Resnick NM
    JAMA Intern Med; 2015 Nov; 175(11):1865-6. PubMed ID: 26524746
    [No Abstract]   [Full Text] [Related]  

  • 38. Biennial [corrected] IV zoledronic acid (Reclast) for prevention of osteoporosis.
    Med Lett Drugs Ther; 2009 Jun; 51(1315):49. PubMed ID: 19556940
    [No Abstract]   [Full Text] [Related]  

  • 39. Osteoporosis drugs not linked to atrial fibrillation.
    Harv Heart Lett; 2009 Apr; 19(8):6. PubMed ID: 19685565
    [No Abstract]   [Full Text] [Related]  

  • 40. Bone diseases: bisphosphonates in osteoporosis--beyond 5 years.
    Papapoulos SE
    Nat Rev Rheumatol; 2013 May; 9(5):263-4. PubMed ID: 23591488
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.